Biomerica (BMRA) AI Stock Analysis

• Market Cap: $8.22M
• Dividend Yield: N/A
• Average Volume (3M): 46.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.47
• Revenue Growth: 5.05%
• EPS Growth: 26.13%
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -0.48
• Shares Outstanding: 2,545,762
• 10 Day Avg. Volume: 71,704
• 30 Day Avg. Volume: 46,353
• PEG Ratio: -0.07
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.49
• Enterprise Value/Market Cap: 1.31
• Enterprise Value/Revenue: 0.48
• Enterprise Value/Gross Profit: 14.06
• Enterprise Value/Ebitda: -0.49
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: $3.00 ▼(-7.12%Downside)

Biomerica's overall stock score is primarily impacted by its financial challenges, including declining revenues and persistent losses. Technical analysis indicates a bearish trend, while valuation metrics are weak due to negative earnings. The recent corporate event involving a key board appointment is a positive factor, potentially improving governance and strategic direction.

Biomerica Business Overview & Revenue Model

Company Description

Biomerica, Inc. (BMRA) is a global biomedical technology company headquartered in Irvine, California. The company operates in the healthcare sector, focusing on the development, manufacturing, and marketing of diagnostic products designed to enhance early detection and therapeutic monitoring of medical conditions. Biomerica's core offerings include diagnostic tests in areas such as food intolerance, gastrointestinal diseases, and diabetes, among others. These tests are designed for use in clinical laboratories, physician's offices, and for over-the-counter markets.

How the Company Makes Money

Biomerica generates revenue primarily through the sale of its diagnostic and therapeutic products. The company offers a range of products targeting various medical conditions, which are sold to laboratories, hospitals, and healthcare providers. Key revenue streams include the sales of diagnostic test kits for food intolerance and gastrointestinal disorders, which are distributed both domestically and internationally. Biomerica also engages in partnerships and collaborations with other healthcare organizations and research institutions to enhance product development and expand market reach. The company aims to leverage its innovative product pipeline and global distribution network to drive sales and increase market share.

Biomerica Financial Statement Overview

Summary

Biomerica is facing significant challenges with persistent losses and negative cash flows. While there is some balance sheet stability due to a positive equity position and low debt-to-equity ratio, the ongoing cash burn and slow revenue growth highlight financial vulnerabilities.

Income Statement

The income statement reveals ongoing challenges with negative net income and EBIT, indicating persistent losses. Revenue growth has been minimal, with a modest increase in the latest TTM period. Gross profit margins remain low, reflecting pricing pressures or higher costs. There is a slight improvement in EBITDA margin, but overall profitability remains weak.

Balance Sheet

The balance sheet shows some stability with a positive equity position and a low debt-to-equity ratio. The equity ratio is healthy, suggesting a solid capital structure. However, total assets have been declining, and liquidity could be a concern given the reduction in cash reserves over time.

Cash Flow

Cash flow remains a significant concern with negative operating and free cash flows, indicating ongoing cash burn. The free cash flow to net income ratio remains unfavorable, highlighting inefficiencies in cash management. While there's been some cash from financing activities, the reliance on external funding is a potential risk.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	5.68M	5.42M	5.34M	18.87M	7.20M	6.69M
Gross Profit	765.00K	611.00K	446.00K	2.98M	496.98K	1.78M
EBITDA	-4.69M	-5.99M	-6.74M	-3.94M	-7.06M	-2.27M
Net Income	-4.85M	-5.98M	-7.14M	-4.53M	-6.47M	-2.34M
Balance Sheet
Total Assets	7.38M	9.25M	14.45M	11.37M	11.82M	17.26M
Cash, Cash Equivalents and Short-Term Investments	3.06M	4.17M	9.72M	5.92M	4.20M	8.64M
Total Debt	543.00K	785.00K	1.08M	1.38M	1.62M	1.78M
Total Liabilities	1.84M	2.66M	2.73M	3.05M	2.59M	3.05M
Stockholders Equity	5.53M	6.59M	11.72M	8.32M	9.23M	14.21M
Cash Flow
Free Cash Flow	-4.25M	-5.48M	-5.55M	-650.87K	-5.55M	-4.42M
Operating Cash Flow	-4.22M	-5.36M	-5.47M	-480.53K	-5.25M	-4.30M
Investing Cash Flow	-61.00K	-115.00K	-78.00K	-170.34K	-295.58K	-118.93K
Financing Cash Flow	2.04M	-81.00K	9.39M	2.39M	1.11M	12.37M

Biomerica Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Neutral. The current price of 3.23 is below the 20-day moving average (MA) of 3.24, below the 50-day MA of 3.38, and below the 200-day MA of 3.61, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 46.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BMRA.

Biomerica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAVM	54 Neutral	$10.22M	0.84	-499.57%	―	-33.92%	―
VVOS	53 Neutral	$22.56M	―	-450.47%	―	9.47%	81.37%
SSKN	52 Neutral	$10.76M	―	-151.23%	―	3.30%	31.84%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
BMRA	49 Neutral	$8.22M	―	-72.70%	―	5.05%	26.13%
CODX	39 Underperform	$9.64M	―	-56.80%	―	-91.22%	11.84%

Biomerica Corporate Events

Biomerica Appoints Eric B. Chin to Board

On June 4, 2025, Cathy Coste resigned from Biomerica‘s Board of Directors, and Eric B. Chin was appointed as an independent member, serving as Chairperson of the Audit Committee. Mr. Chin, an experienced financial executive, is expected to strengthen Biomerica’s corporate governance and financial oversight as the company scales its commercialization efforts. His extensive background in healthcare finance, including his role as CFO of Akido Labs, positions him to contribute significantly to Biomerica’s strategic objectives.

Biomerica Announces Reverse Stock Split Effective April 21

On April 16, 2025, Biomerica announced a 1-for-8 reverse stock split effective April 21, 2025, to increase the bid price of its common stock and maintain its Nasdaq listing. This move will reduce the number of outstanding shares from approximately 20.4 million to 2.5 million, while the number of authorized shares remains unchanged. The reverse stock split aims to enhance Biomerica’s market position by ensuring compliance with Nasdaq’s minimum bid price requirements.